NDA 210498 · Array Biopharma INC
Mektovi
Binimetinib · Oral
NovelOrphanLast checked: Nov 19, 2026Latest source record: Mar 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 27, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
133
8 Phase 3, 18 recruiting
FAERS reports
7,953
5,553 serious, 1,246 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 20, 2025.
MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. [see Dosage and Administration (2.1) ] .
Mechanism: Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models. Binimetinib and encorafenib target two different kinases in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2025 Supplement 11 · Efficacy OrphanLetterLabelMedication Guide
- Sep 12, 2024 Supplement 10 · Efficacy OrphanLabelLetter
- Oct 11, 2023 Supplement 9 · Efficacy OrphanLabelLetter
- Jan 23, 2019 Supplement 1 · Efficacy OrphanLabelLetter
- Jun 27, 2018 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLabelLetter
1 products under this application
- MEKTOVI · BINIMETINIB 15MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Binimetinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01909453 · 921 participants · Start Sep 12, 2013 · Primary completion Nov 9, 2016
Drug: LGX818; MEK162 and 1 more · For: Melanoma
Sites: Birmingham, Alabama; Tucson, Arizona; Fayetteville, Arkansas · 282 sites in all
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Pivotal-lookingActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT05270044 · 815 participants (planned) · Start May 2, 2022 · Primary completion Mar 31, 2027
Drug: Encorafenib and Binimetinib; Placebo to match Encorafenib ; Placebo to match Binimetinib · For: Melanoma
Sites: CABA, Argentina; Mar del Plata, Argentina; Ciudad Autonoma Bs As, Argentina · 155 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
PfizerPfizer (PFE)
NCT02928224 · 702 participants · Start Oct 13, 2016 · Primary completion Feb 11, 2019
Drug: Encorafenib; Binimetinib and 4 more · For: BRAF V600E-mutant Metastatic Colorectal Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Duarte, California · 418 sites in all
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01763164 · 402 participants · Start Jul 12, 2013 · Primary completion Dec 1, 2015
Drug: MEK162; Dacarbazine · For: Metastatic or Unresectable Cutaneous Melanoma
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Altamonte Springs, Florida · 229 sites in all
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT03803553 · 400 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 2026
Drug: FOLFIRI Protocol; Nivolumab Protocol and 2 more · For: Metastatic Colon Cancer; Stage III Colon Cancer
Sites: Boston, Massachusetts; New York, New York · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use976
- death836
- nausea731
- fatigue611
- diarrhoea579
- pyrexia556
- product use in unapproved indication524
- vomiting420
- rash407
- neoplasm progression395
- serous retinal detachment359
- malaise233
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 10 |
| 2018 | 258 |
| 2019 | 1,355 |
| 2020 | 1,273 |
| 2021 | 914 |
| 2022 | 923 |
| 2023 | 969 |
| 2024 | 849 |
| 2025 | 844 |
| 2026 | 556 |
Recalls
1 FDA enforcement reports for this application.
Mar 8, 2023 · Class III · Ongoing
Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mektovi (Binimetinib)
2024 spending
$96.2M
Beneficiaries
1,364
7,307 claims
Per beneficiary
$70,514
$84.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,497,193 |
| 2021 | $64,201,143 |
| 2022 | $73,003,223 |
| 2023 | $56,654,059 |
| 2024 | $96,181,636 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, et al. · Eur J Cancer 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phaseߙ3 BEACON CRC trial.
Kopetz S, Murphy DA, Pu J, et al. · Nat Med 2024 · Clinical Trial, Phase III, Multicenter Study
- Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto PA, Mandalà M, Ferrucci PF, et al. · NEJM Evid 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, et al. · Lancet Oncol 2017 · Clinical Trial, Phase III, Comparative Study
Sponsor: Array Biopharma INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.